tetano
Editor, Senior Moderator
World J Gastroenterol
. 2022 Jul 7;28(25):2802-2822.
doi: 10.3748/wjg.v28.i25.2802.
Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity
Chiranjib Chakraborty[SUP] 1 [/SUP], Ashish Ranjan Sharma[SUP] 2 [/SUP], Manojit Bhattacharya[SUP] 3 [/SUP], Kuldeep Dhama[SUP] 4 [/SUP], Sang-Soo Lee[SUP] 5 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leads to a severe respiratory illness and alters the gut microbiota, which dynamically interacts with the human immune system. Microbiota alterations include decreased levels of beneficial bacteria and augmentation of opportunistic pathogens. Here, we describe critical factors affecting the microbiota in coronavirus disease 2019 (COVID-19) patients. These include, such as gut microbiota imbalance and gastrointestinal symptoms, the pattern of altered gut microbiota composition in COVID-19 patients, and crosstalk between the microbiome and the gut-lung axis/gut-brain-lung axis. Moreover, we have illustrated the hypoxia state in COVID-19 associated gut microbiota alteration. The role of ACE2 in the digestive system, and control of its expression using the gut microbiota is discussed, highlighting the interactions between the lungs, the gut, and the brain during COVID-19 infection. Similarly, we address the gut microbiota in elderly or co-morbid patients as well as gut microbiota dysbiosis of in severe COVID-19. Several clinical trials to understand the role of probiotics in COVID-19 patients are listed in this review. Augmented inflammation is one of the major driving forces for COVID-19 symptoms and gut microbiome disruption and is associated with disease severity. However, understanding the role of the gut microbiota in immune modulation during SARS-CoV-2 infection may help improve therapeutic strategies for COVID-19 treatment.
Keywords: COVID-19; Gut microbiota; Inflammation; Therapeutic.
. 2022 Jul 7;28(25):2802-2822.
doi: 10.3748/wjg.v28.i25.2802.
Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity
Chiranjib Chakraborty[SUP] 1 [/SUP], Ashish Ranjan Sharma[SUP] 2 [/SUP], Manojit Bhattacharya[SUP] 3 [/SUP], Kuldeep Dhama[SUP] 4 [/SUP], Sang-Soo Lee[SUP] 5 [/SUP]
Affiliations
- PMID: 35978881
- PMCID: PMC9280735
- DOI: 10.3748/wjg.v28.i25.2802
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leads to a severe respiratory illness and alters the gut microbiota, which dynamically interacts with the human immune system. Microbiota alterations include decreased levels of beneficial bacteria and augmentation of opportunistic pathogens. Here, we describe critical factors affecting the microbiota in coronavirus disease 2019 (COVID-19) patients. These include, such as gut microbiota imbalance and gastrointestinal symptoms, the pattern of altered gut microbiota composition in COVID-19 patients, and crosstalk between the microbiome and the gut-lung axis/gut-brain-lung axis. Moreover, we have illustrated the hypoxia state in COVID-19 associated gut microbiota alteration. The role of ACE2 in the digestive system, and control of its expression using the gut microbiota is discussed, highlighting the interactions between the lungs, the gut, and the brain during COVID-19 infection. Similarly, we address the gut microbiota in elderly or co-morbid patients as well as gut microbiota dysbiosis of in severe COVID-19. Several clinical trials to understand the role of probiotics in COVID-19 patients are listed in this review. Augmented inflammation is one of the major driving forces for COVID-19 symptoms and gut microbiome disruption and is associated with disease severity. However, understanding the role of the gut microbiota in immune modulation during SARS-CoV-2 infection may help improve therapeutic strategies for COVID-19 treatment.
Keywords: COVID-19; Gut microbiota; Inflammation; Therapeutic.